Risk factors include female gender, increased age, cardiovascular disease, diabetes mellitus, constipation, irritable bowel syndrome, thrombophilia, history of abdominal aortic aneurysm repair, constipation-inducing drugs, immunomodulators, and other illicit drug use [1,2,3]
Novo immediately threatened to sue, and then the FDA said that it plans to take decisive steps to limit access to the active ingredients in popular GLP-1 drugs like Wegovy, Ozempic and Zepbound
The drug increased the likelihood of achieving at least 5% body weight loss but was associated with higher rates of mild-to-moderate gastrointestinal side effects
A type of melanoma called nodular melanoma grows vertically from the first stages of its development
[Multiple acyl-CoA dehydrogenase deficiency (MADD): a curable cause of genetic muscular lipidosis]